In elucidating the
Our analytical research validates the bearish argument for Amicus in the short term yet supports the bullish case in the long haul. In the second half of 2015, the stock enjoyed substantial gains, followed by the tumultuous tumbling in share price due to the FDA rejection of its lead molecule, migalastat (Galafold).
Based in Cranbury, New Jersey, Amicus Therapeutics (NASDAQ: FOLD), a biotechnology at the forefront of individualized medicine, is focusing on the development of a novel chaperone therapeutic - that either stabilizes a defective protein by itself or in combination with existing enzyme replacement therapies ("ERTs").
Current data indicate that these sequelae involve organisms in an unusual state designated persistence, in which metabolic and genetic activity are modified to yield a largely antimicrobial-refractory organism (3, 4).Functional genomics makes use of the wealth of data produced by genome sequencing and transcriptomic projects and entails the development and application of global scale approaches to study gene function.In the past decade, we have witnessed remarkable advancements in technologies that have revolutionized many high-throughput research methods in unraveling gene function at genome scale.In this study, we tested the hypothesis that pollen is beneficial for honey bees challenged with the parasitic mite Varroa destructor associated to the Deformed Wing Virus.First, we studied the effects of pollen on the survival of infested bees, under laboratory and field conditions, and observed that a pollen rich diet can compensate the deleterious effects of mite parasitization.